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 3 
Abstract  4 
Objective: To investigate the risk of chronic kidney disease (CKD) stage 4-5 and dialysis 5 
treatment on incidence of foot ulceration and major lower extremity amputation, in 6 
comparison to CKD stage 3. 7 
Methods: In this retrospective study, all individuals who visited our hospital between 2006 8 
and 2012 because of CKD 3 to 5 or dialysis treatment were included. Medical records were 9 
reviewed for incidence of foot ulceration and major amputation. The time from CKD 3, CKD 10 
4-5 and dialysis treatment until incidence of first foot ulceration and first lower extremity 11 
amputation was calculated and analyzed by Kaplan Meier curves and multivariate Cox 12 
proportional hazards model. Diabetes mellitus, peripheral arterial disease, peripheral 13 
neuropathy and foot deformities were included for potential confounding. 14 
Results: A total of 669 individuals were included: 539 in CKD 3, 540 in CKD 4-5, and 259 in 15 
dialysis treatment (individuals could progress from one group to the next). Unadjusted foot 16 
ulcer incidence rates / 1000 patients / year were 12 (CKD 3), 47 (CKD 4-5) and 104 17 
(dialysis); p<.001. In multivariate analyses, the hazard ratio for incidence of foot ulceration in 18 
CKD 4-5 was 4.0 (95%CI 2.6-6.3), and in dialysis treatment 7.6 (95%CI 4.8-12.1) when 19 
compared to CKD 3. Hazard ratios for incidence of major amputation were 9.5 (95%CI 2.1-20 
43.0) and 15 (95%CI 3.3-71.0) respectively.  21 
Conclusions: CKD 4-5 and dialysis treatment are independent risk factors for incidence of 22 
foot ulceration and major amputation when compared to CKD 3. Maximum effort is needed 23 
in daily clinical practice to prevent foot ulcers and their devastating consequences in all 24 
individuals with CKD 4-5 or dialysis treatment. 25 
26 
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Introduction  1 
Individuals with chronic kidney disease (CKD) are at high risk of foot ulceration and major 2 
lower extremity amputation [1-3]. The highest risk has been found for individuals on dialysis 3 
treatment with diabetes mellitus [1-4]. However, this has only been investigated in patients 4 
with diabetes mellitus and end-stage renal disease (i.e. CKD stage 4 and 5). It is not clear if 5 
this high risk is also present in patients without diabetes mellitus, and if individuals with CKD 6 
4-5 without dialysis treatment are at higher risk for foot ulceration and major amputation 7 
compared to individuals in earlier stages of CKD. 8 
Most research concerning incidence of foot ulceration focuses on patients with diabetes, as 9 
diabetic foot ulceration is one of the major complications of diabetes [1-3,5]. However, 10 
patients with CKD without diabetes have comparable prevalence rates of risk factors 11 
compared to patients with diabetes without CKD [1-3]. As less than half of the patients with 12 
CKD have diabetes [2,3], the risk of CKD 4-5 and dialysis treatment for foot ulceration and 13 
major amputation warrants further investigation in a population reflective of daily clinical 14 
practice, i.e. inclusive of patients with and without diabetes. 15 
Given the association between renal function and foot ulceration in patients with diabetes, and 16 
the increase in foot ulcers that is already seen in the period before dialysis treatment [8], it can 17 
be hypothesized that CKD 4-5 without dialysis treatment is also an independent risk factor for 18 
foot ulceration and major amputation. If such an increased risk is found, preventive measures 19 
should be part of daily clinical practice for all individuals progressing from CKD 3 to CKD 4-20 
5.  21 
The aim of this study is study to investigate the risk of both CKD 4-5 and dialysis treatment 22 
for incidence of FU and LEA, in comparison to CKD 3, and with respect to other relevant risk 23 
factors. 24 
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Materials and methods 1 
This retrospective study was conducted in the department of nephrology, Ziekenhuisgroep 2 
Twente (Hospital Group Twente), the Netherlands. The research deemed exempt from review 3 
of an ethics committee and patient consent due to the retrospective character and the use of 4 
existing medical files only. The research activities of this study were consistent with the 5 
principles of the Declaration of Helsinki. 6 
The eGFR was used to determine the stage of CKD corresponding to the KDOQI staging 7 
scheme [9]. The eGFR was estimated using the Modification of Diet in Renal Disease 8 
(MDRD) equation [10]. CKD 3 was defined as an eGFR between 59 and 30 without dialysis 9 
treatment for more than three months; CKD 4-5 was defined as an eGFR below 30 without 10 
dialysis treatment for more than three months; dialysis treatment was defined as either 11 
peritoneal dialysis or hemodialysis treatment. 12 
All individuals who visited our hospital between September 2006 and September 2012 with 13 
CKD 3 to 5 or undergoing dialysis treatment were enrolled from the hospital broad electronic 14 
medical records system. Individuals were followed from their first visit until: termination of 15 
dialysis treatment, they moved to another hospital, the end of the study period (September 16 
2012), or when death occurred. Individuals could progress from either CKD 3 to CKD 4-5, or 17 
from CKD 4-5 to dialysis treatment. Individuals progressing to the next group were censored 18 
from the analyses in their previous group at that moment. When a non-healed ulcer was 19 
present at the moment of progressing to the next group, they were excluded from the analysis 20 
in this new group. For example: When incidence of the ulcer occurred during CKD 4-5 and 21 
this ulcer did not heal before dialysis treatment started, then the individual was excluded from 22 
analysis in the dialysis treatment group.  23 
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Foot ulceration was defined as all non-traumatic interruptions of the epithelium, or traumatic 1 
interruptions with impaired wound healing, occurring below the malleoli. All foot ulcers were 2 
treated in a multidisciplinary team in line with the international guidelines [11]. Major 3 
amputation was defined as all amputations proximal to the ankle joint. Amputations that were 4 
the result of trauma, oncology, complex regional pain syndrome or congenital causes were 5 
excluded, leaving amputations resulting from ulceration, infection and/or ischemia.  6 
Peripheral Arterial Disease (PAD) was defined as intermittent claudication, critical limb 7 
ischemia, surgical revascularization or amputation because of PAD; the Rutherford 8 
classification was not available. Peripheral neuropathy was defined as ‘loss of protective 9 
sensation’, when a failed monofilament or tuning fork test was present [11]. Foot deformity 10 
was defined as either hallux valgus deformity, hammer toe, claw toe, pes cavus, pes planus, 11 
prominent metatarsal heads, or dislocated metatarsophalangeal joints. Myocardial ischemia 12 
was defined as either a diagnosis of myocardial infarction or instable angina. Cerebrovascular 13 
accident (CVA) was defined as either a diagnosis of CVA or transient ischemic attack. 14 
Smoking status was defined based on presence of medical records with a status of smoking. 15 
Current smoking status and former smoking status were combined as a positive smoking 16 
history. If the smoking status was negative or not present, a negative smoking history was 17 
noted. Total cholesterol was obtained from laboratory results at the start of CKD 3, CKD 4-5 18 
and dialysis treatment.  19 
Characteristics from the three groups (CKD 3, CKD 4-5, dialysis treatment) were compared 20 
using ANOVA for continuous variables and Pearson’s Χ2 or Fisher’s exact test for categorical 21 
variables. Unadjusted incidence foot ulcer incidence rates were calculated for number of 22 
events per 1000 patients / year. Time analyses were made for incidence of foot ulceration and 23 
major amputation in the three groups using Kaplan Meier curves and multivariate Cox 24 
regression models. For univariate analysis, the following confounders were used: Diabetes 25 
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mellitus, PAD, peripheral neuropathy, history of foot ulceration (i.e. before the first known 1 
date in that specific group), history of amputation (i.e. before the first known date in that 2 
specific group), foot deformity, history of myocardial infarction, hypertension, history of 3 
CVA, smoking, total cholesterol, age and sex. Confounders with univariate P-values <.15 4 
were selected for inclusion in the multivariate analysis. The multivariate model was stepwise 5 
formed into a parsimonious Cox proportional hazards model. A P-value <.05 was considered 6 
statistically significant. All analyses were performed using SPSS (version 20.0; SPSS, 7 
Chicago, IL). 8 
Results 9 
Inclusion and sample size 10 
A total of 2010 individuals visited our hospital during the study period with CKD 3 to 5. Due 11 
to the large number of individuals with CKD 3 (n=1889), we obtained a random selection 12 
with SPSS, blinded for outcomes. After randomization, 539 individuals remained in the group 13 
of CKD 3. 14 
We included 669 individuals in our study: 539 individuals in the group of CKD 3, 540 in the 15 
group of CKD 4-5 (of which 411 individuals who progressed from CKD 3), and 259 in the 16 
group of dialysis treatment (of which 159 who progressed from CKD 3 and 99 who 17 
progressed from CKD 4-5). 18 
Characteristics of analysed groups  19 
No clinically relevant differences were found between the groups (Table I). Of all individuals 20 
undergoing dialysis, 83.3 percent underwent hemodialysis, and 28.7 percent underwent 21 
peritoneal dialysis (data not in Table).  22 
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Foot ulceration  1 
Two individuals in CKD 4-5 and eight individuals in dialysis treatment were excluded 2 
because of presence of a non-healed foot ulcer at the start of these groups. A statistically 3 
significant rise in unadjusted foot ulcer incidence rates was seen from CKD 3 to dialysis 4 
treatment, for all ulcers, and for ischemic, infected and deep ulcers as well (Table II). Higher 5 
unadjusted foot ulcer incidence rates were found within the three groups for individuals with 6 
diabetes, PAD, peripheral neuropathy, and foot deformity (Table II). Figure 1 represents the 7 
Kaplan Meier curve for incidence of foot ulceration. Log rank test showed significant 8 
differences between CKD 3, CKD 4-5 and dialysis treatment with a P-value <.001.  9 
Table III represents the univariate and multivariate analysis for incidence of foot ulceration. 10 
Nine confounders met the criteria of a P-value <.15 in univariate analysis and were included 11 
in multivariate analysis. After fitting into a parsimonious model, diabetes mellitus, PAD, 12 
peripheral neuropathy and history of foot ulceration remained in the multivariate analysis. 13 
After multivariate analysis, a significant greater risk for foot ulceration was found for both 14 
CKD 4-5 and dialysis treatment when compared to CKD 3 (Hazard Ratio (HR) 4.0 (95% 15 
Confidence Interval (CI) 2.6-6.3) and 7.6 (95%CI 4.8-12.1) respectively). When dialysis 16 
treatment was directly compared to CKD 4-5, a significant greater risk was found (HR: 1.9 17 
(95%CI 1.3-2.7)). 18 
Major lower extremity amputation 19 
Figure 2 represents the Kaplan Meier curve for major amputation. Log rank test showed 20 
significant differences between CKD 3, CKD 4-5 and dialysis treatment with a P-value <.001. 21 
Table IV represents the univariate and multivariate analysis for major amputation. Nine 22 
confounders met the criteria of a P-value <.15 in univariate analysis and were included in 23 
multivariate analyses. A history of major amputation was excluded because the univariate 24 
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analysis could not be interpreted with a HR of 0.49 and a 95% CI from zero till endless. After 1 
fitting into a parsimonious model, PAD, peripheral neuropathy, history of foot ulceration and 2 
hypertension were left in the multivariate analysis. After multivariate analysis, a significant 3 
greater risk for major amputation was found for both CKD 4-5 and dialysis treatment when 4 
compared to CKD 3 (HR 9.5 (95%CI 2.1-43.0) and 15 (95%CI 3.3-71.0) respectively). When 5 
dialysis treatment was directly compared to CKD 4-5, no significant different risk was found 6 
(HR 1.6 (95%CI 0.7-3.7)). 7 
Discussion 8 
In this retrospective study, fourfold and almost eightfold increases in risks were found for 9 
incidence of foot ulceration in individuals with CKD 4-5 or dialysis treatment respectively, 10 
when compared to individuals with CKD 3. Similar high risks were found for major 11 
amputation. In multivariate analyses, this increased risk was found to be irrespective of 12 
known risk factors, most notably diabetes mellitus.   13 
These findings are in line with previous studies showing a continuum risk for foot problems 14 
in individuals with chronic kidney disease, with the greatest risk for those on dialysis 15 
treatment [4,6-8]. In addition to these studies, we have shown that this risk is found in a 16 
population representative of daily clinical practice, including individuals with as well as 17 
without diabetes mellitus. Whereas the importance of preventive foot care is widely 18 
acknowledged for individuals with diabetes without CKD, this has so far received little 19 
attention for individuals with CKD without diabetes. Given the fourfold increase for foot 20 
ulceration in risk found for CKD 4-5 without dialysis treatment, preventive foot care should 21 
be made available for all individuals with CKD 4-5, not only for those with diabetes. In many 22 
countries, patients with CKD but without diabetes are not entitled to preventive foot care such 23 
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as podiatry. We believe this contributes to the development of preventable foot ulcers and 1 
amputation. 2 
Patients with end-stage renal disease and foot ulcers have high rates of failure of foot salvage, 3 
resulting in high rates of amputation and mortality [12-15]. Early recognition of foot ulcers in 4 
these individuals is important to prevent these devastating consequences. Some promising 5 
results have been shown in studies investigating the effect of preventive programs in 6 
individuals on dialysis treatment [16-18]. However, these preventive programs should not 7 
only target individuals on dialysis treatment, but also those with CKD 4-5. The increased risk 8 
and high incidence rates found in our study indicate that maximum effort to prevent foot 9 
ulcers should be given to all individuals with CKD 4-5. 10 
The retrospective design of our study is a limitation. All variables were obtained from 11 
medical files, of which completeness can not be guaranteed. Additionally, variables such as 12 
the Rutherford classification, use of aspirin and statines, and information on smoking 13 
cessation were not available for all patients. By reading all files, operation reports and letters 14 
to the general practitioners, maximum effort possible has been given to obtain all available 15 
information. Known confounders were controlled for in multivariate analyses, such as 16 
diabetes mellitus, peripheral arterial disease and a history of foot ulceration, but it can not be 17 
ruled out that other confounders may have played a role. The low incidence of major 18 
amputation in CKD 3, CKD 4-5 and dialysis treatment led to relatively broad 95% confidence 19 
intervals in our study, which limits firm statistical conclusions. Because of the small 20 
proportion of ethnic groups in our population, we did not have to correct for influences of 21 
ethnic groups in our analyses. 22 
In conclusion, in this retrospective study we showed that CKD 4-5 and dialysis treatment are 23 
independent risk factors for incidence of foot ulceration and lower extremity amputation when 24 
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compared to CKD 3. Maximum effort is needed in daily clinical practice to prevent foot 1 
ulcers and their devastating consequences in all individuals with CKD 4-5 or dialysis 2 
treatment, with or without diabetes. 3 
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Table I: Characteristics of individuals with CKD 3, CKD 4-5 or dialysis treatment 1 
Characteristic CKD 3 CKD 4-5 Dialysis treatment P-value 
N 539 540 259  
Male sex 58.1 56.3 60.6 .51 
Mean age ± SD 
(years) 
64.4 ± 11.7 64.8 ± 13.3 64.2 ± 13.9 .75 
Diabetes mellitus 38.8 37.6 38.6 .92 
Peripheral arterial 
disease 
25.5 22.2 26.6 .32 
Peripheral 
neuropathy 
24.5 25.7 29.7 .28 
History of foot 
ulceration 
5.0 9.3 15.8 <.001 a,b,c 
History of lower 
extremity 
amputation 
0.4 0.7 2.3 .02 b 
Foot deformity 13.4 12.4 13.9 .82 
History of 
myocardial 
ischemia 
34.7 31.9 28.2 .18 
Hypertension 68.8 66.7 66.0 .65 
History of CVA 26.0 25.9 25.5 .99 
Smoking 41.2 41.3 38.2 .67 
Mean total 
cholesterol ± SD 
(mmol / L) 
5.2 ± 1.3 4.9 ± 1.4 4.1 ± 1.2 <.001 a,b,c 
Note: Numbers are % or as indicated; a = CKD 3 vs CKD 4-5 significantly different with P-2 
value < .05; b = CKD 3 vs. dialysis treatment significantly different with P-value < .05; c = 3 
CKD 4-5 vs. dialysis treatment significantly different with P-value < .05. 4 
5 
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Table 2: Unadjusted foot ulcer incidence rates / 1000 patients / year  1 
 2 
 CKD 3 CKD 4-5 Dialysis 
treatment 
P-value a 
All ulcers 12 (7-16) 47 (37-57) 104 (77-131) <.001 
Ischemic ulcers 3 (1-5) 15 (9-21) 46 (28-64) <.001 
Infected ulcers 6 (3-10) 15 (9-21) 27 (14-41) .007 
Deep ulcers (tendon/bone) 4 (1-6) 15 (9-21) 35 (19-50) .007 
Diabetes 23 (13-33) 91 (65-117) 219 (146-291) <.001 
No diabetes 5 (2-9) 25 (16-35) 57 (33-81) .007 
P-value b <.001 <.001 <.001  
PAD 29 (15-43) 98 (62-134) 182 (109-255) .02 
No Pad 6 (3-10) 35 (24-45) 80 (52-107) <.001 
P-value b <.001 <.001 .002  
Peripheral neuropathy 26 (12-41) 94 (61-128) 171 (109-233) .02 
No peripheral neuropathy 8 (4-12) 34 (24-45) 74 (47-102) .002 
P-value b .002 <.001 .002  
Foot deformity 36 (14-58) 90 (43-137) 220 (90-350) .03 
No foot deformity 9 (5-13) 42 (31-52) 93 (66-120) <.001 
P-value b .001 .02 .02  
Note: Values are: unadjusted foot ulcer incidence rate / 1000 patients / year (95% confidence 3 
interval); a: P-value of the difference between the three groups (CKD 3 – CKD 4-5 – Dialysis 4 
treatment); b: P-value of the difference between individuals with or without the risk factor 5 
within the group. 6 
7 
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Table III: Hazard ratios for incidence foot ulceration in all individuals 1 
 Univariate analysis Multivariate analysis 
Variable HR (95% CI) P-value HR (95% CI) P-value 
CKD group (CKD 3 ref)     
     CKD 4-5 3.8 (2.4 – 5.9) <0.001 4.0 (2.6 – 6.3) <.001 
     Dialysis treatment 8.0 (5.1 – 13) <0.001 7.6 (4.8 – 12.1) <.001 
Diabetes mellitus 3.3 (2.4 – 4.6) <0.001 2.8 (1.9 – 3.9) <.001 
Peripheral arterial 
disease 
2.7 (1.9 – 3.6) <0.001 2.2 (1.6 – 3.1) <.001 
Peripheral neuropathy 2.9 (2.1 – 3.9) <0.001 1.6 (1.2 – 2.3) .005 
History of foot ulceration 4.3 (2.9 – 6.5) <0.001 2.3 (1.5 – 3.5) <.001 
History of lower 
extremity amputation 
5.2 (2.5 – 11.0) <0.001   
Foot deformity 2.2 (1.5 – 3.2) <0.001   
History of myocardial 
ischemia 
1.5 (1.1 – 2.0) 0.02   
Hypertension 0.8 (0.6 – 1.2) 0.29   
History of CVA 0.8 (0.5 – 1.1) 0.19   
Smoking 0.9 (0.7 – 1.3) 0.67   
Total cholesterol 0.7 (0.6 – 0.8) <0.001   
Age 1.0 (1.0 – 1.0) 0.13   
Sex (men as reference) 1.0 (0.8 – 1.4) 0.85   
Note: Variables with P-value <.15 in univariate analysis were included in the multivariate 2 
analysis. Multivariate analysis was step wised formed into a parsimonious model. HR = 3 
Hazard Ratio; CI = Confidence Interval.  4 
5 
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Table IV: Hazard ratios for incidence lower extremity amputation in all individuals 1 
 Univariate analysis Multivariate analysis 
Variable HR (95% CI) P-value HR (95% CI) P-value 
CKD group (CKD 3 ref)     
      CKD 4-5 10.0 (2.2 – 45.0) 0.003 9.5 (2.1 – 43.0) .004 
      Dialysis treatment 22.0 (4.8 – 100.0) <0.001 15.0 (5.3 – 71.0) .001 
Diabetes mellitus 2.3 (1.1 – 5.2) <0.001   
Peripheral arterial 
disease 
5.0 (2.3 – 11.0) <0.001 3.8 (1.7 – 8.6) .002 
Peripheral neuropathy 6.1 (2.7 – 14.0) <0.001 3.2 (1.3 – 7.4) .008 
History of foot 
ulceration 
13.0 (5.9 – 28.0) <0.001 6.8 (2.9 – 16.0) <.001 
Foot deformity 1.3 (0.4 – 3.7) 0.65   
History of myocardial 
ischemia 
1.8 (0.8 – 3.9) 0.13   
Hypertension 0.4 (0.2 – 1.0) 0.04 0.3 (0.1 – 0.7) .005 
History of CVA 0.8 (0.3 – 2.0) 0.60   
Smoking 1.8 (0.8 – 3.8) 0.16   
Total cholesterol 0.6 (0.4 – 0.9) 0.02   
Age 1.0 (1.0 – 1.1) 0.19   
Sex (men as reference) 0.4 (0.2 – 1.0) 0.05   
Note: Variables with P-value <.15 in univariate analysis were included in the multivariate 2 
analysis. Multivariate analysis was step wised formed into a parsimonious model. HR = 3 
Hazard Ratio; CI = Confidence Interval. 4 
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